Apyx Medical (APYX) Q1 2026 Earnings Transcript

Apyx Medical reported Q1 revenue of $12.5 million, up 32% year over year, with Surgical Aesthetics revenue rising 36% to $10.7 million and gross margin expanding to 63.5% from 60.1%. Management raised 2026 revenue guidance to $59 million-$60 million from $57.5 million-$58.5 million and reiterated that FDA 510(k) clearance for AYON power liposuction is expected this quarter. The quarter also showed improving operating leverage, with adjusted EBITDA loss narrowing to $0.3 million and cash at $31.1 million, while international revenue jumped 63%.

Analysis

APYX is transitioning from a single-product recovery story into a platform adoption story, and that matters because platform upgrades typically re-rate medical device names faster than pure consumable growth. The hidden inflection is not the quarter itself but the installed-base conversion: once AYON becomes the default upgrade path for legacy customers, every incremental account should carry a higher mix of consumables, better retention, and lower incremental sales friction. That creates operating leverage even if unit growth moderates, which helps explain why margin expansion can continue despite tariffs and international mix drag.

The bigger second-order effect is market expansion, not just share gain. Power liposuction is likely to unlock a physician cohort that previously would not evaluate AYON at all, so the FDA event should be treated as a demand-unlocking catalyst, not a simple label add-on. If management is right that adoption is still early, then the next 2-3 quarters could show an acceleration in system placements and a disproportionate lift in consumables as newly converted accounts ramp utilization.

The main bear case is that current enthusiasm is being pulled forward by a favorable GLP-1 narrative, while procedure demand could normalize if consumer spending weakens or if the initial converted cohort is smaller than implied. The OEM decline is strategically rational but creates a near-term reported growth headwind later in the year, so headline revenue momentum may decelerate even if the core Surgical Aesthetics engine improves. Also, gross margin guidance already embeds tariff pressure; any further escalation would hit a company this small more than the market appreciates because there is limited operating scale to absorb it.

Consensus is likely underestimating how much of the story is a channel reconfiguration rather than end-demand noise. The strongest setup is not to chase after every strong quarter, but to own the next proof point: label expansion plus evidence of broader-than-Renuvion account penetration. If those two happen together, the stock can move on multiple expansion as investors start capitalizing a longer runway instead of a one-year launch cycle.

Key Decisions for Investors

• Go long APYX for a 3-6 month catalyst window into FDA 510(k) clearance; downside is capped by cash and improving burn, upside is a rerating if power-lipo unlocks a new physician cohort and the market starts capitalizing recurring consumables.
• Structure APYX call spreads rather than outright shares if implied vol remains elevated: bullish asymmetry into the label decision with defined risk, and the stock should react sharply if management proves the platform can expand beyond existing Renuvion users.
• Pair trade: long APYX / short a slower-growth medtech equipment name with weaker innovation cadence over the next 1-2 quarters; the thesis is that APYX has a cleaner near-term product catalyst and more obvious operating leverage.
• If APYX rallies hard on the FDA event, fade strength only after confirmation that new-account adoption stalls; otherwise hold for the next leg because the real monetization is consumables and international registration, which is a 6-18 month runway.
• Watch for any tariff escalation or margin guide miss as the key risk trigger; if gross margin slips below the 62% floor, reassess quickly because the equity is priced for continuing operating leverage.